People

Services

Industries

Firm

About

Knowledge

Careers

News

Events

Contact

Connect

Privacy Policy

Disclaimer

Terms of Use

Accessibility

Payments

Legal

Calgary

Toronto

Edmonton

Ottawa

Vancouver

New York

Montréal

Christian P. Gauthier

M&A & Capital Markets Lawyer | IPOs

Partner

Kwang Lim

Corporate and Securities Lawyer at Bennett Jones Vancouver

Vancouver Managing Partner

Generative AI is taking the venture capital world by storm. Despite the slump in overall VC funding, investor interest in AI is intensifying. PitchBook notes that "in the world of startup valuations, there's generative AI—and everything else." The Wall Street Journal describes the current environment as "ChatGPT fever . . . Amid broader venture-capital doldrums, it is boom times for startups touting generative artificial intelligence tech." As VC investors look to the generative AI market and companies seek funding, there are several things to consider including valuations, the ever evolving regulatory landscape and a heightened need for robust diligence and corporate governance processes.

Booming Venture Capital Investment in Generative AI Considerations for Investors and Companies

Booming Venture Capital Investment in Generative AI: Considerations for Investors and Companies

Gordon N. Cameron

Canadian Corporate & Securities Lawyer

Principal, Head of New York Office, Bennett Jones (US) LLP

Thomas A. Bauer

Tax Lawyer | M&A, Reorganizations & Cross-Border Deals

Partner 

Xenia Wong

Equity & Debt Securities Lawyer | Canadian Law

Principal, Bennett Jones (US) LLP

The special purpose acquisition company (SPAC) IPO boom of 2021 fizzled in 2022 as SPAC IPO activity declined sharply—a trend that will likely continue in 2023. In 2021, there were a record-breaking 613 SPAC IPOs whereas, as of March 2023, there have only been seven SPAC IPOs. This marked decrease in SPAC IPO activity has been driven by rising interest rates, inflation and changes in the regulatory landscape due to increased scrutiny by the SEC.

Canada CrossBorder DeSPAC Transactions What US Listed SPACs and Canadian Companies Need to Know

Canada Cross-Border De-SPAC Transactions: What U.S.-Listed SPACs and Canadian Companies Need to Know

Linda Misetich Dann

Securities, Corporate Finance, M&A and Mining Transaction Lawyer at Bennett Jones Toronto

Harinder S. Basra

Corporate & Securities Lawyer | M&A

Calgary Managing Partner

<a rel="noopener noreferrer" rel="noopener noreferrer" href="https://www.canadianlawyermag.com/practice-areas/corporate-commercial/ma-activity-slips-in-q3-but-year-to-date-numbers-better-than-before-pandemic-bennett-jones-lawyers/370559" target="_blank">Canadian Lawyer</a> reports on Bennett Jones' Q3 look at the M&A landscape. Linda Misetich Dann, Christian Gauthier and Harinder Basra say there is a lot of interest in dealmaking, with the latest numbers on M&A activity beating those from before the pandemic. M&A activity has slowed in the first nine months of 2022.

M A Activity YearToDate Is Better Than Before Pandemic

M&A Activity Year-To-Date Is Better Than Before Pandemic

While Canadian M&A activity slowed in Q3, many companies and investors continue to have the appetite and capital to do M&A transactions, including private equity funds who continue to seek accretive opportunities to deploy capital in a number of sectors in the Canadian economy. As was the case throughout the first half of 2022, deals are being done and opportunities are there, but investors are showing restraint and gone are the days of doing a deal at any cost.

Canadas M A Landscape Q3 2022 Its Not If Its When

Canada's M&A Landscape Q3 2022: It's Not If, It's When

Serge Dupont

Senior Advisor at Bennett Jones Ottawa

Senior Advisor

Policy and business leaders in 2026 are confronting disruptive global forces that pose daunting economic and financial risks while also transforming markets and creating avenues for growth over the next years.

Economic Outlook Mid Year 2026

A Changing World: New Risks, New Opportunities

2026 Mid-Year Economic Outlook

Alison G. FitzGerald

International Arbitration Lawyer at Bennett Jones Ottawa

Nasra Moumin

Commercial Litigation Lawyer at Bennett Jones Toronto

Associate

Global trade policy is rapidly reshaping the regulatory and commercial landscape for life sciences companies. This update explores how evolving US tariff measures, national security reviews, CUSMA renewal uncertainty and expanding export controls are affecting pharmaceutical and medical device manufacturers operating across borders. The authors also examine Canada&rsquo;s response and the growing compliance, supply chain and market access challenges facing the sector in 2026 and beyond.

The Impact of Global Trade on the Life Sciences Sector

Vincent M. de Grandpré

IP Lawyer | Life Sciences & Tech

Melissa M. Dimilta

Intellectual Property Lawyer at Bennett Jones Toronto

Partner, Trademark Agent

As part of a deeply interconnected global sector, the life sciences industry in Canada is undergoing significant change alongside broad macroeconomic and geopolitical shifts.&nbsp;The Bennett Jones Life Sciences team looks at the top issues and developments affecting the industry in 2026.

2026 Life Sciences outlook

Legal and Market Trends to Watch This Year

Life Sciences Outlook 2026

Emily P. Kettel

Cross-border collaborations are central to the life sciences industry, but they can also raise complex questions about patent infringement liability in Canada. This update examines the Federal Court&rsquo;s recent decision in Adeia Guides Inc v Videotron Ltd and its implications for companies involved in the development, supply and commercialization of patented products and services. The authors explore how Canadian law approaches common design infringement, experimental use exemptions and the potential liability of foreign partners whose activities contribute to products ultimately sold in Canada.

Life Sciences Collaborations and the Risk of Joint Patent Infringement

Aaron E. Sonshine

Corporate Finance, Mergers and Acquisitions and Corporate Governance Lawyer at Bennett Jones Toronto

The life sciences sector is experiencing a renewed wave of M&amp;A activity driven by patent expiries, expanding investor appetite and growing demand for innovative therapies and technologies. Drawing on insights shared at the Bloom Burton &amp; Co. Healthcare Investor Conference, this update explores the key trends shaping dealmaking in Canada and globally, including increased competition for assets, rising private transactions and growing investment in emerging markets such as China. The author also examines why current market conditions point to continued momentum across the sector in the second half of 2026.

Christian Gauthier and Thomas Bauer Comment on Energy Trusts in the Globe and Mail

From the Same Authors